Get started
Author

Patricia Vella Bonanno

Observed names: Bonanno, Patricia Vella, P Vella Bonanno, P. Vella Bonanno, P.V. Bonanno, Patricia Vella-Bonanno, Vella Bonanno, Patricia
ORCID: 0000-0002-6064-1323
Observed ORCID: 0000-0002-6064-1323
OpenAlex ID: A5003628873
Policies for biosimilar uptake in Europe: An overview
2017 · Evelien Moorkens, Arnold G. Vulto, et al. · PLoS ONE · 381
PDF
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
2018 · Brian Godman, Anna Bucsics, et al. · Frontiers in Public Health · 167
PDF
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
2017 · Alessandra Ferrario, Diāna Arāja, et al. · PharmacoEconomics · 132
PDF
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
2018 · Tomasz Bochenek, Vafa Abilova, et al. · Frontiers in Pharmacology · 118
PDF
Ethical considerations in the regulation and use of herbal medicines in the European Union
2024 · Anthony Raphael Gatt, Patricia Vella Bonanno, et al. · Frontiers in Medical Technology · 86
PDF
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
2021 · Brian Godman, Andrew Hill, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 83
PDF
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
2021 · Evelien Moorkens, Brian Godman, et al. · Frontiers in Pharmacology · 76
PDF
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
2016 · Michael Ermisch, Anna Bucsics, et al. · Frontiers in Pharmacology · 56
PDF
Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
2019 · Patricia Vella Bonanno, Anna Bucsics, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 51
PDF
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
2019 · Brian Godman, Andrew Hill, et al. · Generics and Biosimilars Initiative Journal · 48
PDF
Utilisation of the ESMO-MCBS in practice of HTA
2016 · C. Wild, N. Grössmann, et al. · Annals of Oncology · 47
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
2017 · Patricia Vella Bonanno, Michael Ermisch, et al. · Frontiers in Pharmacology · 46
PDF
The European Researchers’ Network Working on Second Victim (ERNST) Policy Statement on the Second Victim Phenomenon for Increasing Patient Safety
2024 · Jose Mira, Irene Carillo, et al. · Public health reviews · 43
PDF
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
2019 · Caridad Pontes, Corinne Zara, et al. · Applied Health Economics and Health Policy · 40
PDF
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
2016 · Winnie de Bruijn, Cristina Ibáñez, et al. · Frontiers in Pharmacology · 30
PDF
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries
2022 · Alice Pisana, Björn Wettermark, et al. · Frontiers in Pharmacology · 20
PDF
Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products
2009 · John Joseph Borg, Jean-Louis Robert, et al. · Journal of Pharmacy & Pharmaceutical Sciences · 18
PDF
Utilisation Trend of Long‐Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
2021 · Brian Godman, Magdalene Wladysiuk, et al. · BioMed Research International · 17
PDF
Medication errors through a national pharmacovigilance database approach: A study for Malta
2013 · Amy Tanti, Miriam Camilleri, et al. · International Journal of Risk & Safety in Medicine · 13
Risk Management of Medication Errors: Improving the Quality of Pharmacotherapeutic Practice
2025 · Richard Anthony Despott, Patricia Vella Bonanno, et al. · Pharmacology Research & Perspectives · 9
PDF
Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues
2022 · Brian Godman, Biljana Tubic, et al. · Journal of Applied Pharmaceutical Science · 8
Patient safety and the second victim phenomenon in nursing and medical curricula: A qualitative study
2025 · Einav Srulovici, Mary-Elizabeth Tumelty, et al. · International Journal of Nursing Studies Advances · 4
Variation in the prices of oncology medicines across Europe and the implications for the future
2021 · Brian Godman, Steven Simoens, et al. · Generics and Biosimilars Initiative Journal · 4
PDF
Patients’ experiences of medicines on initiation of antineoplastic agents for the treatment of colorectal cancer: a qualitative study
2021 · Alison Brincat, Patricia Vella Bonanno, et al. · BMJ Open · 3
PDF
A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
2021 · Patricia Vella Bonanno, Vincent Cassar, et al. · Frontiers in Pharmacology · 3
PDF
Works count: 53
Citation count: 1,520
H-index: 17
I10-index: 19
Year
Topic
Type